Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 3, H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Rigel ...
Four months ago, Rigel Pharmaceuticals spent just $2 million—plus ponying up another $233 million in potential milestones—to acquire Forma Therapeutics’ leukemia drug Rezlidhia. On Thursday, Rigel got ...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced publication of the final data from the Phase 1/2 ARROW ...
6don MSN
Jim Cramer blesses Rigel Pharmaceuticals as a spec as “it’s doing better than people realize”
Jim Cramer reviewed Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) while breaking down 16 stocks for a market facing higher energy ...
Rigel Pharmaceuticals (NASDAQ:RIGL) is gearing up to announce its quarterly earnings on Tuesday, 2025-11-04. Here's a quick overview of what investors should know before the release. Analysts are ...
Rigel Pharmaceuticals' strategic acquisitions of GAVRETO and REZLIDHIA, along with strong TAVALISSE sales, position the company for significant growth and potential profitability. Despite historical ...
Rigel’s IRAK1/4 inhibitor, R289, has shown promising results in a Phase 1b trial for relapsed/refractory lower-risk myelodysplastic syndrome (LR-MDS). The initial data presented at ASH 2024 ...
SOUTH SAN FRANCISCO, Calif., Nov. 7, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter ended September 30, 2023, including sales of ...
The real question is whether growing product sales can outpace increasing R&D expenses. Due to the chronic nature of ITP, patients cycle through a variety of treatment options. Patients often stop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results